Introduction: National transplant registries routinely focus on centre-specific patient and graft survival rates following renal transplantation. However other outcomes such as graft function (as measured by eGFR), haemoglobin and blood pressure are also important quality of care indicators. Methods: Renal transplant activity, incident graft survival data and donor information were obtained from NHS Blood and Transplant. Laboratory and clinical variables and prevalent survival data were obtained from the UK Renal Registry. Data were analysed separately for prevalent and one year post-transplant patients. Results: The numbers of live and deceased kidney donors increased in 2010. The death-censored graft failure rate fell slightly to 2.4% and the transplant patient death rates remained stable at 2.5 per 100 patient years. There was centre variation in outcomes including eGFR and haemoglobin in prevalent and 1 year post-transplant patients. Analysis of prevalent transplants by chronic kidney disease stage showed 13.7% with an eGFR <30 ml/min/1.73 m 2 and 1.5% with an eGFR <15ml/min/1.73 m 2 . Of those with CKD stage 5T, 36.1% had haemoglobin concentrations <10.5g/dl, 22.9% phosphate concentrations 51.8mmol/L and 6.2% adjusted calcium concentrations 52.6mmol/L. Malignancy (23%) and infection (22%) remained the commonest two causes of death in prevalent transplant patients. Conclusion: Significant variations in clinical outcomes (unadjusted for patient-specific variables) amongst kidney transplant recipients continued to exist in the UK and may reflect differences in healthcare delivery between renal centres.
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Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the UK Transplant Registry, held by the Organ Donation and Transplantation Directorate (ODT) of NHS Blood and Transplant (NHSBT). The UK Renal Registry (UKRR) has performed additional analyses of renal transplant recipient follow-up data examining demographics, clinical and biochemical variables. NHSBT records all the information regarding the episode of transplantation (donor and recipient details) and the UKRR holds additional information on key clinical and biochemical variables in renal transplant recipients. The co-operation between these two organisations results in a comprehensive database describing the clinical care delivered to renal transplant patients within the UK. This further allows for the comparison of key outcomes between centres and provides insight into the processes involved in the care of such patients in the UK.
This chapter is divided into 6 sections: (1) transplant activity, waiting list and survival data; (2) transplant demographics; (3) clinical and laboratory outcomes; (4) analysis of prevalent patients by chronic kidney disease (CKD) stage; (5) eGFR slope analysis; and (6) causes of death in transplant recipients. Methodology, results and conclusions of these analyses are discussed in detail for all six sections separately.
The UK Renal Registry methodology is described elsewhere [1] . The UKRR collects quarterly clinical data via an electronic data extraction process from hospital-based renal IT systems on all patients receiving renal replacement therapy. Throughout the chapter the number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable.
Unless otherwise specified, prevalent transplant patients were defined as patients with a functioning renal transplant on the 31st December 2010.
Transplant activity, waiting list activity and survival data Introduction NHSBT prospectively collects donor and recipient data around the episode of transplantation. They also request transplant centres provide an annual paper based data return on the status of the recipient's graft function. This enables ODT to generate comprehensive analyses of renal transplant activity and graft survival statistics.
NHSBT attributes a patient to the centre that performed the transplant operation irrespective of where the patient was cared for before or after the procedure and hence only reports on transplant centre performance.
Methods
There are 23 UK adult renal transplant centres, 19 in England, 2 in Scotland and 1 each in Northern Ireland and Wales.
Comprehensive information from 1999 onwards concerning the number of patients on the transplant waiting list, the number of transplants performed, the number of deceased kidney donors (donor after brainstem death and donor after circulatory death), living kidney donors, patient survival and graft survival is available on the NHSBT website (http://www. organdonation.nhs.uk/ukt/statistics/statistics.asp).
Results
During 2010, 2,724 kidney or kidney plus other organ transplants were performed. The absolute numbers of living kidney donor and donor after circulatory death transplants continued to increase and comprised 37.7% and 20.2% of all kidney transplants performed respectively. There was also an increase in numbers of transplants from donors There are small differences in one and five year riskadjusted patient and graft survival rates amongst UK renal transplant centres (table 3. 2). These graft survival MacPhee/Webb/Casula/Udayaraj The following sections need to be interpreted in the context of variable repatriation policies; some transplant centres continue to follow up and report on all patients they transplant, whereas others refer patients back to non-transplant centres for most or all ongoing posttransplant care. Some transplant centres only refer back Belfast  92  96  88  92  94  100  97  93  B QEH  88  96  82  89  95  98  85  97  Bristol  95  96  86  85  98  99  95  98  Camb  92  98  86  89  98  99  93  97  Cardff  94  98  86  88  94  98  86  97  Covnt  95  96  89  92  95  100  86  96  Edin  88  94  82  83  95  98  92  96  Glasgw  94  96  84  82 patients when their graft is failing. The time posttransplantation that a patient is referred back to their local centre varies between transplant centres. The UKRR is able to detect duplicate patients (being reported from both transplant and referring centres) and in such situations care is attributed to the referring centre. This process may result in some discrepancies in transplant numbers particularly in Oxford/Reading and Clywd/ Liverpool RI.
Methods
Four centres (Bangor, Colchester, Liverpool Aintree, Wirral) did not have any transplant patients and were excluded from some of the analyses. Their dialysis patients were included in the relevant dialysis population denominators. The nine Scottish centres only submit limited laboratory data to the UKRR and were not included in the analyses on post-transplant outcomes.
For the analysis of primary renal diagnosis (PRD) in transplant recipients, a few centres were excluded from some of the take-on years because of concerns relating to the reliability of PRD coding (with these centres submitting a high percentage of uncertain aetiology codes).
Information on patient demographics (age, gender, ethnicity and PRD) for patients in a given renal centre was obtained from UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for them during 2010. The prevalence of transplant patients in areas covered by individual primary care trusts (PCT) or Health Boards/Social Care Areas (HB) was estimated based on the post code of the registered address for patients on renal replacement therapy (RRT). Data on ethnic origin, supplied as Patient Administration System (PAS) codes, were retrieved from fields within renal centre IT systems. For the purpose of this analysis, patients were grouped into Whites, South Asians, Blacks, Others and Unknown. The details of ethnicity regrouping into the above categories are provided in appendix H: Coding http://www.renalreg.com/ report-area/report 2011/appendix-H.pdf. The UKRR requires a standard set of data items regarding comorbid conditions at the time of commencement of renal replacement therapy and first registration of the patient with the UKRR.
Results and discussion
Prevalent transplant numbers across the UK are described in table 3.3.
The prevalence of renal transplant recipients in each PCT/HB in England, Northern Ireland (Health and Social Care Trust Areas), Scotland (Health Boards) and Wales (Local Health Boards) and the proportion of prevalent patients according to modality in the renal centres across the UK is described in tables 3.4 and 3.5 respectively. After standardisation for age and gender, unexplained variability was evident in the prevalence of renal transplant recipients, with some areas having higher than the predicted number of prevalent transplant patients per million population and others lower. There are a number of potential explanations for these inconsistencies, including geographical differences in access to renal transplantation in the UK. This has previously been analysed in detail by the UKRR [2] and is currently the focus of a large national study (Access to Transplant and Transplant Outcome Measures-ATTOM).
The proportion of prevalent RRT patients with a transplant relative to the number on dialysis has been fairly stable since at least 2000.
Age and gender
The gender ratio amongst incident and prevalent transplant patients has remained stable for at least the last ten years (table 3.6, figure 3.1). Note absolute patient numbers differ from those published in previous reports as a result of additional data validation and reallocation of patients. The average age of incident transplant patients has steadily increased during the same time period. There has also been a gradual increase in the average age of prevalent transplant patients, which could reflect the increasing age at which patients are transplanted and/or improved survival after renal transplantation over the last few years. The prevalent transplant patient workload across the UK had increased to 24,739 patients at the end of 2010. The continued expansion of this patient group means there is a need for careful planning by renal centres for future service provision and resource allocation. MacPhee/Webb/Casula/Udayaraj MacPhee/Webb/Casula/Udayaraj The primary renal diagnosis of patients receiving kidney transplants in the UK has remained stable over the last 5 years (table 3.7).
Ethnicity
It was difficult to compare the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group because data on ethnicity were missing in a considerable number of patients who were classified as ethnicity 'unknown' (table 3.8). The percentages of patients with unknown ethnicity between 2005 and 2009 provided in this year's chapter are different from those in last year's chapter [3] ; this reflects retrospective input of ethnicity data, improving data completeness.
Clinical and laboratory outcomes
Introduction There continues to be marked variation in the completeness of data (tables 3.9a, 3.9b) reported by each renal centre, particularly for blood pressure. Better data records (or possibly better extraction of data held within renal IT systems) would facilitate more meaningful comparisons between centres and help to determine MacPhee/Webb/Casula/Udayaraj the causes of between-centre differences in outcomes. For this reason, along with differences in repatriation policies of prevalent transplant patients between centres as highlighted previously, caution needs to be exercised when comparing performance between centres.
The 72 renal centres in the UK comprise 52 centres in England, 5 in Wales, 6 in Northern Ireland and 9 in Scotland. Centres in Scotland only provide summary information and therefore laboratory outcome data for comparisons were not available for the Scottish renal centres. Four centres (Bangor, Colchester, Liverpool Aintree, Wirral) were reported as having no transplanted patients and were therefore excluded. After exclusion of these 13 centres, prevalent patient data from 59 renal centres across the UK were analysed.
For the one year post-transplant analyses, in which patients were assigned to the centres that performed their transplant, the two Scottish transplant centres were excluded as they only submit limited biochemical data to the UKRR. After excluding these 2 transplant centres, one year outcomes are described for 21 transplant centres across the UK. the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and non-transplant centre, care was allocated to the non-transplant centre. Patients with a functioning transplant of less than 3 months duration were excluded from analyses. For haemoglobin, estimated glomerular filtration rate (eGFR), corrected calcium, phosphate and blood pressure (BP), the latest value in quarter 3 or quarter 4 of 2010 was used.
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the original 4-variable MDRD formula was used (with a constant of 186) to calculate eGFR from the serum creatinine concentration as reported by the centre (unless otherwise stated). A wide variety of creatinine assays are in use in clinical biochemistry laboratories in the UK, and it is not possible to ensure that all measurements of creatinine concentration collected by the UKRR are harmonised. Although many laboratories are now reporting assay results that have been aligned to the isotope dilution-mass spectrometry standard (which would necessitate use of the modified MDRD formula), this was not the case at the end of 2010. Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation.
One year post-transplant data
Patients who received a renal transplant between 1st January 2003 and 31st December 2009 were assigned according to the renal centre in which they were transplanted. In a small number of instances, the first documented evidence of transplantation in a patient's record is from a timeline entry in data returned from a non-transplant centre, in these instances the patient was reassigned to the nearest transplant centre (table 3.10).
Patients who had died or experienced graft failure within 12 months of transplantation were excluded from the analyses. For patients with more than one transplant during 2003-2009, they were included as separate episodes provided each of the transplants functioned for a year. 238  93  90  92  92  18  Nottm  446  98  54  95  94  87  Oxford  846  99  50  98  98  28  Plymth  275  89  45  92  92  20  Ports  733  94  35  91  88  11  Prestn  391  93  79  93  93  63  Redng  272  98  93  98  93  85  Sheff  561  98  42  98  98  19  Shrew  114  88  78  80  80  4  Stevng  183  94  69  93  90  39  Sthend  67  94  28  93  93  4  Stoke  262  99  98  99  98  31  Sund  154  97  81  98  98  91  Swanse  172  98  71  98  98  38  Truro  148  99  66  98  98 MacPhee/Webb/Casula/Udayaraj For each patient, the most recent laboratory or blood pressure for the relevant 4th/5th quarter (10-15 months) after renal transplantation was taken to be representative of the one year post-transplant outcome. Again, for the purpose of the eGFR calculation patients with valid serum creatinine results but missing ethnicity data were classed as White.
Results and discussion

Post-transplant eGFR in prevalent transplant patients
When interpreting eGFR post-transplantation it is important to remember that estimated GFR formulae only have a modest predictive performance in the transplant population [4] . Median eGFR in each centre and percentage of patients with eGFR <30 ml/min/1.73 m 2 are shown in figures 3.2 and 3.3. The median eGFR was 51.3 ml/min/1.73 m 2 , with 13.8% of prevalent transplant recipients having an eGFR <30 ml/min/1.73 m 2 . Table 3 .11 summarises the proportion of transplant patients with an eGFR <30 ml/min/1.73 m 2 by centre. Whilst local repatriation policies on timing of transfer of care of patients with failing transplants from transplant centres to referring centres might explain some of the differences, it is notable that both transplanting and non-transplant centres feature at both ends of the scale. The accuracy of the 4-variable MDRD equation in estimating GFR 560 ml/min/1.73 m 2 is questionable [5] , therefore a figure describing this is not included in this chapter. There continued to be variation between centres; these data show over-dispersion with 15 centres falling outside the 95% CI of which 8 centres were outside the 99.9% CI. Five centres (Bristol, Cardiff, London St George's, London West, Nottingham) fall outside the lower 99.9% CI suggesting a lower than expected proportion of patients with eGFR <30 ml/min/1.73 m 2 . Liverpool RI, Portsmouth and Preston fall outside the upper 99.9% CI suggesting a higher than expected proportion of patients with eGFR <30 ml/min/1.73 m 2 .
eGFR in patients one year after transplantation
Graft function at one year post-transplantation may predict subsequent long-term graft outcome [6] . The median eGFR of patients one year post-live donor transplantation was 54.1 ml/min/1.73 m 2 . The median eGRF of patients one year post-deceased donor transplant was 50.9 ml/min/1.73 m 2 . MacPhee/Webb/Casula/Udayaraj upward trend in eGFR (p < 0.001) over the time period is noticed with both live and deceased donor transplants. Therefore changing donor demographics, with a higher proportion of live donor transplants more recently, does not explain the upward trend in one year posttransplant eGFR.
Haemoglobin in prevalent transplant patients
Transplant patients have previously fallen under the remit of the UK Renal Association Complications of Chronic Kidney Disease (CKD) guidelines. Updated guidelines regarding the management of anaemia in CKD were published by the association in November 2010 [7] . However, most of the data presented in this chapter pre-dates this and therefore the previous standards are referred to. These state that 'Patients with CKD should achieve a haemoglobin between 10.5-12.5 g/dl' [8] . However, many transplant patients with good transplant function will have haemoglobin concentrations >12.5 g/dl without the use of erythopoiesis stimulating agents, and so it is inappropriate to audit performance using the higher limit.
A number of factors including comorbidity, immunosuppressive medication, graft function, ACE inhibitor use, erythropoietin (EPO) use, intravenous or oral iron use, as well as centre practices and protocols for management of anaemia, affect haemoglobin concentrations in transplant patients. Most of these data are not collected by the UKRR and therefore caution must be used when interpreting analyses of haemoglobin attainment. Two centres (London Barts, London Royal Free) fall outside the upper 99.9% CI and four further centres (Leicester, Liverpool RI, London Kings, London West) fall outside the upper 95% CI indicating a higher than predicted proportion of transplant patients not achieving the haemoglobin target. Eleven centres fall outside the lower 99.9% CI, indicating they perform better than expected with fewer than predicted patients having a haemoglobin <10.5g/dl.
Blood pressure in prevalent transplant patients
In the absence of controlled trial data, the opinionbased recommendation of the UK Renal Association (RA) published in the 2010 guideline for the care of the kidney transplant recipient is that 'Blood pressure should be <130/80mmHg (or <125/75mmHg if proteinuria)' [9] . This blood pressure target is the same as that used in previous annual reports [10] .
As indicated in table 3.9a, completeness for blood pressure data returns was variable and only centres with >50% data returns were included for consideration. Despite this restriction, caution needs to be exercised in interpretation of these results because of the volume of missing data and potential bias, (e.g. a centre may be more likely to record and report blood pressure data electronically in patients with poor BP control). 
Analysis of prevalent patients by CKD stage
Introduction Approximately 2.4% of prevalent transplant patients returned to dialysis in 2010, a similar percentage to that seen over the last 8 years. Amongst patients with native chronic kidney disease, late presentation is associated with poor outcomes, largely attributable to lack of specialist management of anaemia, acidosis, hyperphosphataemia and to inadequate advance preparation for dialysis. Transplant recipients on the other hand, are almost always followed up regularly in specialist trans- plant or renal clinics and it would be reasonable to expect patients with failing grafts to receive appropriate care and therefore have many of their modifiable risk factors addressed before complete graft failure and return to dialysis.
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31st patients on peritoneal dialysis were considered when examining differences in serum phosphate between transplant recipients and dialysis patients. For both the transplant and dialysis cohorts, the analysis used the most recent available value from the last two quarters of the 2010 laboratory data. Table 3 .12 shows that 13.7% of the prevalent transplant population (2,855 patients), had moderate to advanced renal impairment of eGFR <30 ml/min/ 1.73 m 2 . The table also demonstrates that patients with failing grafts achieved UK Renal Association standards for some key biochemical and clinical outcome variables less often than dialysis patients. This substantial group of patients represents a considerable challenge, as resources need to be channelled to improve key outcome variables and achieve a safe and timely modality switch to another form of renal replacement therapy. Introduction Differences in causes of death between dialysis and transplant patients may be expected due to selection for transplantation and use of immunosuppression. Chapter 6 includes a more detailed discussion on causes of death in dialysis patients.
Results and discussion
Methods
The cause of death is sent by renal centres as an ERA-EDTA registry code. These have been grouped into the following categories: cardiac disease, cerebrovascular disease, infection, malignancy, treatment withdrawal, other and uncertain. Some centres have high data returns to the UKRR regarding cause of death, whilst others return no information. Provision of this information is not mandatory.
Adult patients aged 18 years and over, from England or Wales, were included in the analyses on cause of death. Previous analyses were limited to data from centres with a high rate of return for cause of death. When this was compared with an analysis of all the cause of death data on the database, the percentages in corresponding ERA-EDTA categories remained unchanged so the latter data were therefore included. Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 31st December 2010.
Results and discussion Tables 3.14, 3.15 and figure 3 .11 show the differences in the causes of death between prevalent dialysis and transplant patients. Death due to cardiovascular disease is less common in transplanted patients than in dialysis patients, perhaps reflecting the cardiovascular screening undertaken during transplant work-up; transplant recipients are a pre-selected lower risk group of patients. Malignancy is the commonest reported cause of death in transplant recipients (23%), in keeping with current literature regarding post-transplantation malignancy [15] . There has been a reduction over time in the proportion of deaths in transplant patients attributed to cardiovascular or stroke disease (43% in 2003 compared to 23% in 2010) with an increase in the proportion ascribed to infection or malignancy (30% in 2003 compared to 45% in 2010). This change has also been reported in other registries, eg ANZDATA (http://www. anzdata.org.au) and may reflect better management of cardiovascular risk (although table 3.12 shows BP and phosphate management remained suboptimal). Explanations for the rising death rate secondary to malignancy may include the increasing age of transplant recipients and the increased intensity of immunosuppressive regimens leading to complications of over-immunosuppression.
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